Dr. Hussain on the Importance of Genomic Profiling in mCRPC

Video

In Partnership With:

Maha Hussain, MD, FACP, FASCO, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer.

Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine, Division of Hematology and Oncology, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer (mCRPC).

Genomic profiling is critical in men with prostate cancer, says Hussain. Germline and somatic testing could inform not only current treatment selection, but potential future options for patients.

For example, tissue-based testing can identify whether a patient harbors a targetable alteration, Hussain says. The results could inform whether a patient is a candidate for an approved PARP inhibitor or a clinical trial.

Additionally, early implementation of genetic testing could be important for blood relatives of men with prostate cancer, Hussain concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,